Glucagon‐Like Peptide‐1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis
An increased risk of recurrent pancreatitis was observed in high-risk patients receiving GLP1 analogue therapy. These findings align with pharmacovigilance data and support caution when prescribing GLP1 analogues in this population. Prospective studies are warranted to further evaluate this association.
Authors
- Shiri Kushnir (ORCID: https://orcid.org/0000-0003-2359-5249)
- Idit Dotan (ORCID: https://orcid.org/0000-0003-0551-4759)
- Tzippy Shochat (ORCID: https://orcid.org/0000-0002-7576-8327)
- Talia Diker‐Cohen (ORCID: https://orcid.org/0000-0001-6211-2073)
- Bronya Calvarysky (ORCID: https://orcid.org/0009-0008-5124-0748)
- Adi Turjeman (ORCID: https://orcid.org/0000-0003-2200-9922)
- Yaniv Gal
Institutions
- Tel Aviv University (IL)
- Hebrew University of Jerusalem (IL)
- Rabin Medical Center (IL)
Publication Details
- Journal
- Diabetes/Metabolism Research and Reviews
- Published
- 2025-12-14
- DOI
- https://doi.org/10.1002/dmrr.70116
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00